TG ImmunoPharma
June 22, 2026
Theater 3
Type: Company Presentation
Focus Area:
Immunology
TG ImmunoPharma (TGI) is a clinical-stage biotech company to develop breakthrough therapeutics on immunotherapy, T cell engager and NK cell engager. It was founded in 2020 by Dr. Zhigang Tian, one of the global leaders in NK cell receptor/ligand research, and 30-year research in tumor immunology research.
TGI has established a highly innovative pipeline based on our cutting-edge research with 3 programs at Phase 1/IND stage. We have also established innovative proprietary pH-selective TCE platform and ABC-NKer NKCE platform to enhance the safety and efficacy of immunotherapies.
The company operates a nearly 6,000m2 R&D base equipped with core facilities such as SPF animal lab and GMP facilities. It has filed nearly 100 invention patents and has been recognized as one of “China’s Top 500 Hidden Unicorns” and “Specialized and Sophisticated Small and Medium-sized Enterprise”. TGI has raised over RMB 200 million in cumulative financing.
Company HQ City:
Hefei
Company HQ State:
Anhui
Company HQ Country:
China
Year Founded:
2020
Lead Product in Development:
TGI-6, Phase I with IND approvals from both US FDA and China NMPA
TGI-5, Phase I with IND approvals from both US FDA and China NMPA
CEO
Dr. Zhigang Tian, Founder
Dr. Larry Zhu, CEO
Dr. Liusong Yin, CSO
Dr. Haoyu Sun, COO
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
8
When you expect your next catalyst update?
September 2026
What is your next catalyst (value inflection) update?
Phase I progress of TGI-6 and TGI-5
IND of TGI-10, TGI-17 and TGI-18
BD deal of license out
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}